Evidence map›Paper›PMID 32235557›Full record

ArticleMolecules (Basel, Switzerland)2020

Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs.

Ting-Ting Li, Christophe Pannecouque, Erik De Clercq, Chun-Lin Zhuang, Fen-Er Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ting-Ting LiInstitute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China.
Christophe PannecouqueRega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Erik De ClercqRega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium.ORCID 0000-0002-2985-8890
Chun-Lin ZhuangDepartment of Chemistry, Fudan University, Shanghai 200433, China.ORCID 0000-0002-0569-5708
Fen-Er ChenInstitute of Pharmaceutical Science and Technology, Zhejiang University of Technology, Hangzhou 310014, China.
Fudan University · CNRega Institute for Medical Research · BEZhejiang University of Technology · CN

Funding

National Natural Science Foundation of China 21372050Natural Science Foundation of Shanghai 13ZR1402200the Young Elite Scientists Sponsorship Program by the China Association for Science and Technology 2017QNRC061
6 · The paper itself

Abstract

Scaffold hopping is a frequently-used strategy in the development of non-nucleoside reverse transcriptase inhibitors. Herein, CH(CN)-DAPYs were designed by hopping the cyano-methylene linker of our previous published CH(CN)-DABOs onto the etravirine (ETR). Eighteen CH(CN)-DAPYs were synthesized and evaluated for their anti-HIV activity. Most compounds exhibited promising activity against wild-type (WT) HIV-1. Compounds

Indexed as

HIV Reverse TranscriptaseMolecular Docking SimulationReverse Transcriptase InhibitorsAlkynesBenzoxazinesCell LineCyclopropanesHIV-1HumansAlkynesBenzoxazinesCyclopropanesefavirenzHIV Reverse Transcriptasereverse transcriptase, Human immunodeficiency virus 1Reverse Transcriptase InhibitorsCH(CN)-DAPYsHIV-1NNRTIscaffold hoppingstrucutral optimization

Identifiers

PMID32235557
PMCPMC7180830
OpenAlexW3013994046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.